Categories: Technology

Novaerus launches ‘Defend 1050’ – A Versatile Next Gen Air Sterilization System in India

~ Defend 1050 a medical-grade, portable device combining plasma and filter technology to control infections and purify indoor air ~

National, September 10, 2018: Novaerus, an Irish company specializing in non-chemical air disinfection using patented ultra-low energy plasma, announced the launch of theDefend 1050 in India at ISAR conference (Indian Society for Assisted Reproduction) orga zed in Aurangabad, recently.

The latest and strongest of all models – Defend 1050 is a portable, easy to use device ideal for rapid disinfection and purification of the air in large spaces and high-risk situations such as operating-theatres, ICUs, IVF labs, emergency and waiting rooms, and construction zones. The Defend 1050 uses patented Dielectric-barrier discharge (DBD) ultra-low energy plasma technology – a highly effective method of rapid pathogen destruction and a specifically designed multi-stage pre-filters, HEFA filters and Carbon Filter systems to reduce infection, absorb odours, neutralize volatile organic compounds (VOCs), and trap particulate as small as 0.3µm, making it the best for offering both ‘Trap’ and ‘Kill’ technologies of air-purification.

Defend 1050 was launched and displayed for the first time and received an attendance of approximately 600 participants who were from the IVF community to understand the only complete solution for their IVF lab air quality.

As a part of the launch of Defend 1050, Una Ni Raghallaigh, Business Development Director, EMEAA region for Novaerus Inc visited Mumbai and was accompanied by Novaerus’ Indian partner and Representative Mr Dilip Patil, Managing Partner of Trivector Biomed LLP. They introduced the technology and discussed the trialing and implementation strategies for Defend 1050 for controlling airborne infections with some of the notable Indian healthcare establishments such as infection control heads of Sion Hospital (Bombay Municipal Corporation), Thane Municipal Hospital, Lilavati Hospital and Nanavati hospital.

While launching Defend 1050 at ISAR conference, Una Ni Raghallaigh, Business Development Director, EMEAA region for Novaerus Inc said, “With time, we have seen a high contamination rate in the air, which is resulting to an alarming increase in airborne diseases and causing adverse results to human health. The plasma technology brought by Novaerus has been studied by NASA that has shown how the technology is an answer to this crisis.”

To add to her point, Dilip Patil, Managing Director, Trivector Biomed LLP said, “Airborne infections are usually neglected and hence we intend to spread awareness about the adverse effects, it can cause. Novaerus and its plasma technology is a boon not just for IVF labs but for any other critical healthcare divisions as it is the most effective solution with a potential to save lives. We hope to help the public healthcare sectors with this, innovation and through this we would like to contribute to PM Modi’s vision of Swachh Bharat Abhiyan.”

Corporate Comm India(CCI Newswire)

The Pharma Times News Bureau

Recent Posts

Bayer Introduces Bepanthen in India as New Survey Reveals Dry Skin Affects 1 in 2 Indians

·        World's no.1 skincare brand Bepanthen* launches in India, as a solution to tackle India's widespread dry skin…

7 hours ago

Lung Cancer in India: Understanding Risk Factors and the Importance of Early Detection

By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…

1 day ago

10 Winter Skin Care Tips Dermatologists Swear By

Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru  Winter weather brings a host…

4 days ago

Fighting Viral Hepatitis in India: Prevention, Risks, and the Path to Better Health

By Dr. Naveen Ganjoo, Senior Consultant - Hepatology & Integrated Liver Care, Aster RV Hospital…

5 days ago

Hon’ble Prime Minister Shri Narendra Modi Inaugurates LyfiusPharma’s Flagship Penicillin-G Facility at Kakinada, Andhra Pradesh

Under the Production Linked Incentive(PLI)scheme, Lyfius Pharma Private Limited(LyfiusPharma) invested ₹2,500 crores in Penicillin-G( Pen-G)facility…

6 days ago